|
Gadolinium MRA Contrast Agent Linked to NSF and NFD
WARNING: Gadolinium contrast agents have been linked to Nephrogenic Systemic Fibrosis and Nephrogenic Fibrosing Dermopathy (NSF/NFD). NSF is a disease that occurs in patients with kidney failure. The FDA has identified a possible link between NSF/NFD and exposure to gadolinium containing contrast agents used at high doses for a procedure called Magnetic Resonance Angiography (MRA).
Currently, the FDA is aware of 25 cases of NSF/NFD in patients with kidney failure who received Omniscan®, a gadolinium-containing contrast agent, and took the MRA test.
The trade names of the U.S. approved gadolinium-containing contrast agents are: Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. None of these drugs are FDA approved for MRA. The dose of gadolinium-containing contrast agent given to patients undergoing an MRA test is often higher (up to three times) than the approved dose for MRI.
NSF/NFD appears to occur in patients with kidney failure along with high levels of acid in body fluids a condition known as acidosis that is common in patients with kidney failure.
Patients with Gadolinium NSF have tight and rigid skin making it difficult to bend joints. NSF/NFD may also result in fibrosis, or scarring, of body organs resulting in the inability of body organs to work properly and can lead to death. Diagnosis of NSF/NFD is done by looking at a sample of skin under a microscope.
For a free case evaluation, please fill out the form below. An attorney will review your form and may contact you to discuss your legal rights.
Injured Person Information:
Accident / Injury Information:
Case Description*
Please explain exactly what happened, trying to state
as thoroughly as possible who you believe was responsible
and why you believe that person was negligent:
|
Please explain the full extent of the victims injuries:
|
Comments / Additional Information
Is there anything else that would assist us in
understanding the facts of your case?
|
| 
